TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33117895
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy combined with music therapy (10 therapy sessions and related homework)
Study: 33117961
Drug: Transcutaneous tibial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous tibial nerve stimulation; details on dosage and duration not available.
Study: 33119478
Drug: Intraperitoneal radioimmunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal radioimmunotherapy (RIT) with anti-B7H3 murine monoclonal antibody
Study: 33121236
Drug: Danicopan monotherapy
Normalized name: Danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danicopan monotherapy (100-200 mg thrice daily)
Study: 33122543
Drug: Continuous morphine
Normalized name: morphine sulfate Oral Suspension [MST Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous morphine infusions (median duration 20.5 hours) with paracetamol 4 times daily and rescue morphine for unacceptable pain (numerical rating scale ≥4)
Study: 33122898
Drug: Any Triple
Normalized name: WITCH HAZEL 500 mg in 1 g / LIDOCAINE 50 mg in 1 g / PHENYLEPHRINE HYDROCHLORIDE 2.5 mg in 1 g TOPICAL CLOTH [The Pharma C Company Triple Action Hemorrhoidal Pads]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any Triple Combination Therapy
Study: 33123048
Drug: Reduced Environmental
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced Environmental Stimulation Therapy (REST)
Study: 33123384
Drug: Hepatocyte matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatocyte matrix implant
Study: 33124006
Drug: Rosuvastatin 5
Normalized name: rosuvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 5 mg once daily
Study: 33124006
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg once daily
Study: 33124006
Drug: Antiretroviral drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral drugs with known impact on lipid profile (protease inhibitors, efavirenz, cobicistat)
Study: 33125295
Drug: Simplified algorithm
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simplified algorithm for prevention and early treatment of bleeding, differentiation syndrome, and infection; education of oncologists about early deaths in APL; frequent communication between expert and treating physician in the first 2 weeks.
Study: 33125309
Drug: Nivolumab 1
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 1 mg/kg and ipilimumab 3 mg/kg for four cycles, followed by nivolumab maintenance therapy for up to 2 years.
Study: 33125520
Drug: Senolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senolytic treatment targeting senescent cells
Study: 33125520
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of SA-β-gal in subcutaneous adipose tissue
Study: 33125909
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy (taselisib, palbociclib, AZD4547, rilotumumab plus erlotinib, talazoparib, telisotuzumab vedotin)
Study: 33125909
Drug: Anti-PD-1 or
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 or anti-PD-L1 therapy (durvalumab, nivolumab plus ipilimumab)
Study: 33125909
Drug: Docetaxel (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (second line therapy)
Study: 33125909
Drug: Anti-PD-1 or
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 or anti-PD-L1-containing therapies
Study: 33126339
Drug: T-DM1 at
Normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: T-DM1 at 3.6 mg/kg every 3 weeks
Study: 33127750
Drug: Reformulated T3
Normalized name: Tarsum Reformulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated T3 (2.73 µg T3 in 300 µl for 5 consecutive days)
Study: 33128080
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation therapy (EST) of the lower esophageal sphincter (LES)
Study: 33128299
Drug: Pamiparib 20
Normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamiparib 20 mg BID
Study: 33128299
Drug: Pamiparib 40
Normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamiparib 40 mg BID
Study: 33128299
Drug: Pamiparib 60
Normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamiparib 60 mg BID
Study: 33128347
Drug: Avacopan 10
Normalized name: avacopan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avacopan 10 mg plus standard-of-care (SOC)
Study: 33128347
Drug: Avacopan 30
Normalized name: Avacopan
DrugBank: Avacopan (DB15011)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avacopan 30 mg plus standard-of-care (SOC)
Study: 33128347
Drug: Avacopan 30
Normalized name: Avacopan
DrugBank: Avacopan (DB15011)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avacopan 30 mg plus SOC
Study: 33128347
Drug: Avacopan 10
Normalized name: avacopan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avacopan 10 mg plus SOC
Study: 33128873
Drug: 4.0 mg
Normalized name: LORAZEPAM 4.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 mg CH5126766 three times per week
Study: 33128873
Drug: 3.2 mg
Normalized name: menthol 3.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.2 mg CH5126766 three times per week
Study: 33128873
Drug: 4.0 mg
Normalized name: LORAZEPAM 4.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 mg CH5126766 twice per week
Study: 33128873
Drug: 4.0 mg
Normalized name: LORAZEPAM 4.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 mg CH5126766 (various schedules)
Study: 33128903
Drug: Fostemsavir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostemsavir (600 mg twice a day) in combination with failing regimen for 8 days, followed by fostemsavir plus optimised background therapy
Study: 33128903
Drug: Fostemsavir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostemsavir (600 mg twice a day) plus optimised background therapy from day 1
Study: 33130556
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to treatment guidelines
Study: 33131027
Drug: Zolpidem (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (5 or 10 mg) daily for 2 weeks
Study: 33131912
Drug: Ceftriaxone (empirical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (empirical antibiotic)
Study: 33131912
Drug: In vitro-active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro-active antibiotics
Study: 33131933
Drug: Hantavax® (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hantavax® (three primary doses and a booster dose schedule at 0, 1, 2 and 13 months)
Study: 33131933
Drug: Hantavax® (booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hantavax® (booster dose at 13 months)
Study: 33131933
Drug: Hantavax® (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hantavax® (three primary doses)
Study: 33131933
Drug: Hantavax® (booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hantavax® (booster doses)
Study: 33132297
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of Men-ACWY-D vaccine administered 8 weeks apart
Study: 33134951
Drug: Nebulized DAS181
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized DAS181 (4.5 mg) twice a day for 10 days
Study: 33135120
Drug: Daily self-reported
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-reported activity in patients with BD
Study: 33135120
Drug: Daily self-reported
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-reported activity in unaffected relatives (UR)
Study: 33136058
Drug: Injectable Amoxicillin
Normalized name: amoxicillin Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable Amoxicillin every 12 hours plus once-daily injectable Gentamicin
Study: 33136058
Drug: Injectable Ampicillin
Normalized name: ampicillin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable Ampicillin every 6 hours plus once-daily injectable Gentamicin
Study: 33136058
Drug: Injectable Amoxicillin
Normalized name: amoxicillin Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable Amoxicillin plus Gentamicin
Study: 33137019
Drug: PRESERFLO MicroShunt
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRESERFLO MicroShunt implantation with adjunctive mitomycin C (0.4 mg/mL)
Study: 33138835
Drug: Early BC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early BC on treatment post-surgery (Group 1, 89 patients)
Study: 33138835
Drug: Early BC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early BC after completion of adjuvant treatment (Group 2, 108 patients)
Study: 33138835
Drug: Metastatic BC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metastatic BC treatment (Group 3, 102 patients)
Study: 33138848
Drug: Mouthwash containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwash containing antivirals (β-cyclodextrin and Citrox®)
Study: 33139055
Drug: Volasertib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib monotherapy (Cycle 2)
Study: 33139139
Drug: NVX-CoV2373 vaccine
Normalized name: SARS-CoV-2 NVX-CoV2373 vaccine, recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVX-CoV2373 vaccine with Matrix-M™ adjuvant
Study: 33139266
Drug: Avelumab 10
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 10 mg/kg every 2 weeks until disease progression or unacceptable toxicity
Study: 33140664
Drug: Parsaclisib (INCB050465),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsaclisib (INCB050465), a highly selective PI3Kδ inhibitor, used as monotherapy.
Study: 33141094
Drug: Remote titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote titration facilitated by a smartphone-based telemonitoring system
Study: 33141101
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual group (n=10)
Study: 33142850
Drug: Motor program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motor program activating therapy
Study: 33145266
Drug: Apatinib, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib, 500 mg once daily, until disease progression, unacceptable toxicity, consent withdrawal, or death.
Study: 33145616
Drug: Berzosertib (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berzosertib (intravenous infusion)
Study: 33145809
Drug: Low-Dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-Dose CT (LDCT) imaging for osteoporosis screening
Study: 33146624
Drug: Standardized discharge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized discharge prescription forms with 90-day prescriptions and 3 repeats for recommended cardiac medication classes, in combination with education
Study: 33146624
Drug: Longer (>60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer (>60 days) versus shorter prescription durations
Study: 33146628
Drug: Pneumococcal conjugate
Normalized name: pneumococcal conjugate PCV 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal conjugate vaccine against Streptococcus pneumoniae
Study: 33146741
Drug: Cemiplimab 250
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 250 mg every 3 weeks
Study: 33146953
Drug: Electroacupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture treatment on HT-7 for 5 weeks
Study: 33147119
Drug: Sequential imaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential imaging with dual tracers
Study: 33147119
Drug: Sequential use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential use of PET tracers
Study: 33147283
Drug: 3D regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D regimen treatment
Study: 33147613
Drug: RA patients
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RA patients with MTX only or with other medications
Study: 33148235
Drug: 3 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 µg epinephrine applied into the test well
Study: 33148261
Drug: e-Device (certolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: e-Device (certolizumab pegol self-injection)
Study: 33148277
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin administration
Study: 33148277
Drug: IS and
Normalized name: Poliomyelitis and tetanus vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IS and hyperglycemia without treatment
Study: 33148673
Drug: BMS-986178 monotherapy
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-986178 monotherapy (20-320 mg)
Study: 33148673
Drug: BMS-986178 plus
Normalized name: anti-OX40 antibody BMS 986178
DrugBank: anti-OX40 antibody BMS 986178 (DB15773)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986178 plus nivolumab (240-480 mg)
Study: 33148673
Drug: Nivolumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab monotherapy (240-480 mg)
Study: 33148673
Drug: BMS-986178 plus
Normalized name: anti-OX40 antibody BMS 986178
DrugBank: anti-OX40 antibody BMS 986178 (DB15773)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986178 plus ipilimumab (1-3 mg/kg)
Study: 33148693
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four cycles then nivolumab 3 mg/kg every 2 weeks until progression or a maximum of 20 cycles.
Study: 33150319
Drug: Psilocybin-assisted group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin-assisted group therapy (0.3-0.36 mg/kg po) with 8-10 group therapy visits and one psilocybin administration visit
Study: 33150319
Drug: Psilocybin-assisted group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin-assisted group therapy
Study: 33150320
Drug: Vi-DT vaccine
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi-DT vaccine (one or two doses)
Study: 33150320
Drug: Vi-DT vaccine
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi-DT vaccine (two doses)
Study: 33150325
Drug: Chewable mebendazole
Normalized name: mebendazole Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewable mebendazole tablet
Study: 33150325
Drug: Solid mebendazole
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solid mebendazole tablet
Study: 33150390
Drug: Lapatinib 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1250 mg/day for 6 months
Study: 33150779
Drug: High-dose fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fish oil capsules
Study: 33153503
Drug: Deep transcranial
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep transcranial magnetic stimulation (dTMS); specific dosage and duration not available
Study: 33153629
Drug: lenzilumab 600
Normalized name: Lenzilumab
DrugBank: Lenzilumab (DB15148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lenzilumab 600 mg intravenously for three doses
Study: 33153727
Drug: Apararenone (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apararenone (320 mg on day 2, 20 mg/d on days 3-15) with Midazolam (2 mg on days 1 and 15)
Study: 33153727
Drug: Apararenone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apararenone (40 mg/d on days 8-11, 10 mg/d on days 12-27) with Warfarin (25 mg on days 1 and 21)
Study: 33153727
Drug: Apararenone (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apararenone (160 mg on day 11, 10 mg/d on days 12-28) with Digoxin (0.5 mg on days 1 and 24)
Study: 33153960
Drug: OGTT (Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: OGTT (Oral Glucose Tolerance Test)
Study: 33154057
Drug: nab-paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel plus gemcitabine (nab-P+Gem) chemotherapy plus split-course SBRT
Study: 33154417
Drug: Faecal volatile
Normalized name: coal tar pitch volatiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faecal volatile organic compounds (VOCs) analysis
Study: 33154953
Drug: Intranasal application
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal application of nan
Study: 33155938
Drug: macitentan 10
Normalized name: macitentan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: macitentan 10 mg/day
Study: 33155938
Drug: bosentan 250
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bosentan 250 mg/day
Study: 33156244
Drug: Urine Drug
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urine Drug Screen (UDS)
Study: 33158819
Drug: Integrated intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated intervention (INT) which includes pharmacotherapy and a hybrid of behavioural support delivered by trained healthcare practitioners (HCPs) and a web-based application.
Study: 33159216
Drug: Temsirolimus 25
Normalized name: temsirolimus 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus 25 mg IV weekly and Erlotinib 100 mg orally daily (RP2D)
Study: 33159216
Drug: Temsirolimus 15
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus 15 mg IV weekly and Erlotinib 100 mg orally daily (starting dose)
Study: 33159216
Drug: Temsirolimus and
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus and Erlotinib combination
Study: 33159365
Drug: Bisantrene (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisantrene (250 mg/m2)
Study: 39675110
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor agonist
Study: 34861151
Drug: Background therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background therapy
Study: 33161013
Drug: FDG-PET-based dose-painting
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG-PET-based dose-painting technique with SIB-IMRT and concomitant Cisplatin after 2 cycles of induction chemotherapy.
Study: 33161240
Drug: Emactuzumab (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emactuzumab (IV administration, 900 to 2000 mg every two weeks in dose-escalation phase, optimal biological dose of 1000 mg in dose-expansion phase)
Study: 33161258
Drug: Cochlear implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implant (Slim Modiolar) with bimodal stimulation (cochlear implant and hearing aid in contralateral ear) for 6-months postimplant
Study: 33161258
Drug: Bimodal condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimodal condition (cochlear implant and hearing aid)
Study: 33161777
Drug: Galvanic current-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galvanic current-induced vasodilation (CIV) in patients under low-dose aspirin (ASA; ≤ 500 mg/day)
Study: 33161777
Drug: Galvanic current-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galvanic current-induced vasodilation (CIV) in patients not under low-dose aspirin (ASA; ≤ 500 mg/day)
Study: 33163408
Drug: Ablation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablation therapy
Study: 33164349
Drug: Sarilumab 200
Normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 200 mg SC every 2 weeks (Q2W)
Study: 33164349
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from IV to SC sarilumab 200 mg SC Q2W
Study: 33164349
Drug: Continuing sarilumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing sarilumab 200 mg SC Q2W
Study: 33164633
Drug: Age ≥65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age ≥65 years and use of diuretics at discharge
Study: 33164985
Drug: Subcutaneous adipose
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous adipose tissue oxygen partial pressure (pO2) measurement in MHL, MHO, and MUO groups.
Study: 33165001
Drug: Low-dose haemodialysis
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose haemodialysis
Study: 33165001
Drug: Deintensification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deintensification of haemodialysis treatment
Study: 33165001
Drug: Standard-dose haemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose haemodialysis
Study: 33165755
Drug: Antivirals (67.6%)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antivirals (67.6%)
Study: 33165773
Drug: Roxadustat (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (100 mg single dose)
Study: 33165773
Drug: Roxadustat (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (100 mg single dose) after dialysis (P1)
Study: 33165773
Drug: Roxadustat (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (100 mg single dose) before dialysis (P2)
Study: 33168363
Drug: Mediastinal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediastinal and subcutaneous adipose tissue
Study: 33168612
Drug: Nifurtimox (NF)
Normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifurtimox (NF) treatment; children received 10 to 15 mg/kg/day for 60 to 90 days; adults received 8 to 10 mg/kg/day for 30 days
Study: 33168818
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of unconjugated antibody with panitumumab-IRDye800CW
Study: 33169671
Drug: Lung-protective ventilation
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung-protective ventilation with low tidal volume (median 6.3 mL/kg predicted bodyweight, IQR 5.7-7.1)